Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:46:37.121Z.
Calculation as of: 2026-10-06T15:46:37.121Z.
Quote observation: 2026-10-06T15:45:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$193.36M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.57M
EV/Sales Ratio
6611.72x
TTM Avg
8843.11x
3Y Avg
4911.03x
5Y Avg
2972.75x
Market Cap
$215.07M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.44M
EV/Sales Ratio
1.17x
TTM Avg
2.73x
3Y Avg
3.49x
5Y Avg
2.89x
Market Cap
$216.34M
EV/Sales Ratio
9.26x
TTM Avg
17.85x
3Y Avg
16.79x
5Y Avg
16.79x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $202.47M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.90M | 2.82x | 2.41x | 2.22x | 2.09x |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $193.36M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.57M | 6611.72x | 8843.11x | 4911.03x | 2972.75x |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $215.58M | 2.82x | 9.07x | 6.60x | 11.04x |
| Niagen Bioscience Inc (NAGE)vs › | $215.44M | 1.17x | 2.73x | 3.49x | 2.89x |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.34M | 9.26x | 17.85x | 16.79x | 16.79x |
| Alector, Inc. (ALEC)vs › | $217.05M | 13.70x | 7.34x | 5.26x | 6.10x |
| AN2 Therapeutics, Inc. (ANTX)vs › | $189.63M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
